ESC 365 - Challenging the data.

Open Access

Challenging the data.

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

Topic: Endothelial function

Speaker: Professor J. Chapman (Paris, FR) Professor P. Sever (London, GB)

Sponsored by Amgen GmbH

Event: ESC Congress 2017

Congress Presentation

About the speakers

Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

17 presentations

0 follower

Professor Peter S Sever

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 presentations

1 follower

2 more presentations in this session

PCSK9 inhibitors: the story continues.

Speaker: Professor J. Chapman (Paris, FR)

PCSK9 inhibitors: more volumes to come?

Speaker: Professor J. Chapman (Paris, FR)

Access the full session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

Speakers: Professor J. Chapman, Professor P. Sever, Professor J. Chapman, Professor J. Chapman

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by